The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mitochondrial defects including neurodegenerative diseases such as Alzheimer's and Parkinson's or a neoplastic disease such as leukemia.

##STR00001##

The present invention is directed to benzamide-containing compounds of formula I

##STR00001##

or pharmaceutically acceptable salts thereof which inhibit the P2X.sub.7 receptor, and their use in the treatment of depression.

The present invention is directed to benzamide-containing compounds of formula I

##STR00001##

or pharmaceutically acceptable salts thereof which inhibit the P2X.sub.7 receptor, and their use in the treatment of depression.

Disclosed are compounds of formulae: ##STR00001##
and pharmaceutically acceptable salts thereof, wherein the variables, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.

A liquid crystal composition that has a positive dielectric anisotropy and a sufficiently low viscosity and that causes no display defects when used in liquid crystal display devices is provided without decreasing or increasing the refractive index anisotropy or nematic phase-isotropic liquid phase transition temperature. This liquid crystal composition contains at least one compound selected from compounds represented by general formula (LC0) and at least one compound selected from the group consisting of compounds represented by general formulas (LC1) to (LC5). This liquid crystal composition can be used to provide a reliable liquid crystal display device capable of maintaining a high voltage-holding ratio at high temperatures. This liquid crystal display device is highly practical as a liquid crystal display and is effective in achieving quick response without significantly decreasing the cell gap.

A liquid crystal composition that has a positive dielectric anisotropy and a sufficiently low viscosity and that causes no display defects when used in liquid crystal display devices is provided without decreasing or increasing the refractive index anisotropy or nematic phase-isotropic liquid phase transition temperature. This liquid crystal composition contains at least one compound selected from compounds represented by general formula (LC0) and at least one compound selected from the group consisting of compounds represented by general formulas (LC1) to (LC5). This liquid crystal composition can be used to provide a reliable liquid crystal display device capable of maintaining a high voltage-holding ratio at high temperatures. This liquid crystal display device is highly practical as a liquid crystal display and is effective in achieving quick response without significantly decreasing the cell gap.

An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (I) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (I) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like). ##STR00001##

An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (I) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (I) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like). ##STR00001##

A carbon dioxide absorbent containing an amine compound (A) having a heterocyclic structure (X) selected from the group consisting of an oxygen-containing heterocyclic structure and a sulfur-containing heterocyclic structure, a content of the amine compound (A) being 65% by mass or more.

A carbon dioxide absorbent containing an amine compound (A) having a heterocyclic structure (X) selected from the group consisting of an oxygen-containing heterocyclic structure and a sulfur-containing heterocyclic structure, a content of the amine compound (A) being 65% by mass or more.